Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04375774
Other study ID # 2020/15AVR/226
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2020
Est. completion date May 2020

Study information

Verified date May 2020
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Guillaume Lemaire, MD
Phone +3227641870
Email guillaume.lemaire@uclouvain.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The COVID-19 pandemic health crisis forces health institutions to lower their standards of protection as supplies of personal protective equipment decrease despite the safety of front-line workers worldwide . This shortage specifically affects high-quality protective masks, such as those called FFP2. As alternatives, we offer a reusable mask based on a ventilation mask combined with a breathing filter for anesthesia breathing circuits. The purpose of the study is to assess the sealing potential of this mask in the field and possibly prove a non-inferior sealing compared to standard masks type FFP2.


Description:

The ongoing 2020 COVID-19 pandemic challenges healthcare providers (HCP) worldwide with a rapid consumption and shortage of personal protection equipment (PPE), especially high-level filtration respirator masks. Respirators used by HCPs are mainly single use face filtering pieces with at least level P2 protection for single shift use following European EN 149 standards defining protection level against hazardous particles.

In response to the risk of shortage we propose a novel reusable do-it-yourself (DIY) respirator assembled with already widely available components in hospital stocks: a standard breathing filter plugged in an anaesthesia facial mask held in place with a hook ring strapped to a silicone head harness. As reports of a modified full-face snorkelling (MFS) mask used for non-invasive ventilation in infected patients emerged in Italy, we reckon that it could also be used as PPE with a modified valve and breathing filter.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 2020
Est. primary completion date May 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- adult volunteers working in a first line healthcare service with basic knowledge of donning PPE including respirators

- 5 females and 5 males

Exclusion Criteria:

- smoking or unhealthy participants with respiratory affections to avoid breathing difficulties during testing

- any known allergy towards medical silicone or any other material of each component and ingredients used for disinfection of the test area and material between participants

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FFP2
Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
Facial mask
Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
MFS
Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI

Locations

Country Name City State
Belgium Cliniques Universitaires Saint-Luc Brussels

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of airtightness (Fit test) Non inferiority claim over FFP2 Up to 1 week
Secondary User Comfort User face comfort for each type of mask assessed by a assessed by a scoring-cale from 1 to 5 Up to 1 week
Secondary Breathing easiness User respiratory easiness for each type of mask assessed by a scoring-cale from 1 to 5 Up to 1 week
Secondary Field of view quality User field of view quality for each type of mask assessed by a scoring-cale from 1 to 5 Up to 1 week
Secondary Ease of use How the device is user friendly, assessed by a scoring-cale from 1 to 5 Up to 1 week
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2